Summary of 10 new indications/approvals in Heme Malignancies by FDA Oncology in 2023 – Oncology Brothers

Quoting Oncology Brothers on X/Twitter:

“Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by FDA Oncology in 2023:

1. Zanubrutinib

2. Pirtobrutinib

3. Polatuzumab

4. Epcortimab

5. Glofitamab

6. Quizartinib

7. Talquetamab

8. Elranatamab

9. Ivosidenib”

Summary of 10 new indications/approvals in Heme Malignancies by FDA Oncology in 2023 - Oncology Brothers